Lilly Feeds The Beast, But Is Novartis Animal Health Unit Worth The Price?
This article was originally published in The Pink Sheet Daily
$5.4 billion deal boosts Lilly’s Elanco animal health business that adds both geographic scope and better product mix, but some investors snort at the high multiple.
You may also be interested in...
China and emerging markets are expected to come to the fore for Eli Lilly as it works through patent expirations in the United States, while Japan helped despite a weaker yen.
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.